$ANAB
AnaptysBio Inc Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000137005318000027 Filed on May 08, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.830M	$3.950M	$2.050M
YoY Change	62.98%	92.68%	68.03%
% of Gross Profit
Research & Development	$10.58M	$11.81M	$7.935M
YoY Change	46.88%	48.83%	65.8%
% of Gross Profit
Depreciation & Amortization	$70.00K	$54.00K	$39.00K
YoY Change	40.0%	38.46%	-31.58%
% of Gross Profit
Operating Expenses	$14.42M	$15.76M	$9.988M
YoY Change	50.86%	57.76%	66.33%
Operating Profit	-$14.42M	-$15.76M	-$9.988M
YoY Change	464.19%	57.76%	776.91%
Interest Expense	$436.0K	$451.0K	$428.0K
YoY Change	-0.68%	5.37%	272.17%
% of Operating Profit
Other Income/Expense, Net	$797.0K	$671.0K	-$1.447M
YoY Change	-717.83%	-146.37%	-676.49%
Pretax Income	-$13.62M	-$15.09M	-$11.44M
YoY Change	408.13%	31.87%	1185.39%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$13.62M	-$15.09M	-$11.44M
YoY Change	407.38%	31.93%	1187.73%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.57	-$0.63	-$0.75
Diluted Earnings Per Share	-$0.57	-$0.63	-$0.75
COMMON SHARES
Basic Shares Outstanding	23.50M shares	23.81M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$267.9M	$248.2M	$103.5M
YoY Change	151.89%	139.78%	109.93%
Cash & Equivalents	$57.06M	$69.47M	$96.75M
Short-Term Investments	$210.9M	$178.7M	$6.742M
Other Short-Term Assets	$3.800M	$2.200M	$1.700M
YoY Change	-2.56%	29.41%	88.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$271.8M	$251.9M	$110.2M
YoY Change	134.63%	128.72%	114.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.086M	$659.0K	$569.0K
YoY Change	100.0%	15.82%	13.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$32.70M	$61.90M	$20.30M
YoY Change	135.25%	204.93%
Other Assets	$322.0K	$289.0K	$100.0K
YoY Change	222.0%	189.0%	-96.43%
Total Long-Term Assets	$34.20M	$62.89M	$20.96M
YoY Change	134.86%	200.11%	535.03%
TOTAL ASSETS
Total Short-Term Assets	$271.8M	$251.9M	$110.2M
Total Long-Term Assets	$34.20M	$62.89M	$20.96M
Total Assets	$306.0M	$314.8M	$131.1M
YoY Change	134.66%	140.13%	139.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.426M	$2.416M	$2.546M
YoY Change	18.85%	-5.11%	263.71%
Accrued Expenses	$4.837M	$4.405M	$4.330M
YoY Change	49.75%	1.73%	54.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.500M	$7.500M	$1.300M
YoY Change	141.94%	476.92%	225.0%
Total Short-Term Liabilities	$16.79M	$14.34M	$8.126M
YoY Change	66.58%	76.51%	14.45%
LONG-TERM LIABILITIES
Long-Term Debt	$4.100M	$5.800M	$12.70M
YoY Change	-62.73%	-54.33%	182.22%
Other Long-Term Liabilities	$100.0K	$100.0K	$200.0K
YoY Change	-50.0%	-50.0%	-84.62%
Total Long-Term Liabilities	$4.200M	$5.900M	$12.90M
YoY Change	-62.5%	-54.26%	122.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.79M	$14.34M	$8.126M
Total Long-Term Liabilities	$4.200M	$5.900M	$12.90M
Total Liabilities	$21.00M	$20.30M	$21.00M
YoY Change	-0.94%	-3.33%	62.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.7M	-$100.1M	-$66.40M
YoY Change	64.54%	50.79%
Common Stock	$24.00K	$24.00K	$20.00K
YoY Change	20.0%	20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$285.0M	$294.5M	$110.1M
YoY Change
Total Liabilities & Shareholders Equity	$306.0M	$314.8M	$131.1M
YoY Change	134.66%	140.13%	139.69%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$13.62M	-$15.09M	-$11.44M
YoY Change	407.38%	31.93%	1187.73%
Depreciation, Depletion And Amortization	$70.00K	$54.00K	$39.00K
YoY Change	40.0%	38.46%	-31.58%
Cash From Operating Activities	-$8.880M	-$12.48M	-$8.097M
YoY Change	236.36%	54.11%	293.82%
INVESTING ACTIVITIES
Capital Expenditures	-$310.0K	$232.0K	$85.00K
YoY Change	416.67%	172.94%	142.86%
Acquisitions
YoY Change
Other Investing Activities	-$2.760M	$2.380M	-$27.00M
YoY Change	-95.57%	-108.81%
Cash From Investing Activities	-$3.070M	$2.146M	-$27.09M
YoY Change	-95.08%	-107.92%	77285.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	-$80.21M
YoY Change		-100.0%	-8021400.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-480.0K	-$1.383M	$80.70M
YoY Change	-48.39%	-101.71%	-29446.91%
NET CHANGE
Cash From Operating Activities	-8.880M	-$12.48M	-$8.097M
Cash From Investing Activities	-3.070M	$2.146M	-$27.09M
Cash From Financing Activities	-480.0K	-$1.383M	$80.70M
Net Change In Cash	-12.43M	-$11.72M	$45.52M
YoY Change	-81.16%	-125.73%	-2024.01%
FREE CASH FLOW
Cash From Operating Activities	-$8.880M	-$12.48M	-$8.097M
Capital Expenditures	-$310.0K	$232.0K	$85.00K
Free Cash Flow	-$8.570M	-$12.71M	-$8.182M
YoY Change	232.17%	55.34%	291.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2961000	USD
CY2018Q1	anab	Accrued Research And Contract Manufacturing Expenses Current AccruedResearchAndContractManufacturingExpensesCurrent	2842000	USD
CY2018Q1	anab	Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions	30100000	USD
CY2017Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	1601000	USD
CY2018Q1	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	1600000	USD
CY2018Q1	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	1610000	USD
CY2018Q1	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	83000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	52000	USD
CY2017Q1	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	0	USD
CY2018Q1	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	0	USD
CY2017Q1	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	866000	USD
CY2018Q1	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	2260000	USD
CY2017Q1	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	1290000	USD
CY2018Q1	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	0	USD
CY2017Q1	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	4607000	USD
CY2018Q1	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23497680	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO INC
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2323000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2416000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4875000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4405000	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	140000	USD
CY2018Q1	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	133000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3978000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4032000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-426000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-801000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	393017000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	395424000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2327000	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2611000	shares
CY2017Q4	us-gaap	Assets Assets	329364000	USD
CY2018Q1	us-gaap	Assets Assets	314837000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	252696000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	251945000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	801000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	243373000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	242572000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	167218000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	178691000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	75897000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	61884000	USD
CY2017Q1	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81189000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69474000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51292000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96814000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81249000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69534000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	45522000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-11715000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	287	shares
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5204230	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23791000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23817000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23816957	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23791000	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23816957	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23817000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11448000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15887000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	54000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.75
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1588000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1033000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2053000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3947000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	682000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-158000	USD
CY2017Q1	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	-1225000	USD
CY2018Q1	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	0	USD
CY2017Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	847000	USD
CY2018Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	9000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	143000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-388000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	428000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	451000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	122000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1185000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	278000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	297000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329364000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	314837000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14090000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14343000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80704000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1383000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27085000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2146000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8097000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12478000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11435000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-15086000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1447000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	671000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6875000	USD
CY2018Q1	us-gaap	Notes Payable Current NotesPayableCurrent	7500000	USD
CY2017Q4	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	7553000	USD
CY2018Q1	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	5834000	USD
CY2018Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	9988000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	15757000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9988000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15757000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	326000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	530000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	289000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-801000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-801000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	17000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-150000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-156000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	225000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	399000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	280000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	27000000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	32203000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	232000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	11520698	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2688000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2170000	USD
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	194700000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80213000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	34581000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	355000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	72000	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	535000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	75000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4643000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4691000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	659000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1250000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7935000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11810000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85034000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100100000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100120000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2018Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425903	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1481286	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.32
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	23784	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	55.48
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	934141	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	262707	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	221253300	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2655722	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.03
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.06
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.97
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	107.05
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	143336200	USD
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M7D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y0M29D
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	68.50
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9104	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	307581000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	294527000	USD
CY2017Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1429
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15295000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23801000	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of the Business </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities, and at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> have an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$100.1 million</font><font style="font-family:inherit;font-size:10pt;">. Through </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements, proceeds from our Term Loans as discussed in Note 5 below, and the issuance of convertible debt. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Public Offerings and Related Transactions</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">On January 31, 2017, we completed an initial public offering, or IPO, selling </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5,750,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> shares of common stock at </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$15.00</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per share. Proceeds from our initial public offering net of underwriting discounts and commissions were </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$80.2 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In addition, each of the following occurred in connection with the completion of the IPO on January 31, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of all outstanding shares of convertible preferred stock into </font><font style="font-family:inherit;font-size:10pt;">11,520,698</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the conversion of warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock into warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">377,195</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the resultant reclassification of the warrant liability to additional paid-in capital.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, we amended and restated our certificate of incorporation to effect a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> reverse stock split of every outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the reverse stock split. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Public Offering </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 17, 2017, we completed an underwritten public offering selling </font><font style="font-family:inherit;font-size:10pt;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </font><font style="font-family:inherit;font-size:10pt;">$194.7 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions. As part of the underwritten public offering, on November 14, 2017, the underwriters exercised an additional </font><font style="font-family:inherit;font-size:10pt;">271,380</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a discounted price to the public of </font><font style="font-family:inherit;font-size:10pt;">$68.50</font><font style="font-family:inherit;font-size:10pt;"> per share for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$17.6 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001370053-18-000027-index-headers.html	Edgar Link	pending
0001370053-18-000027-index.html	Edgar Link	pending
0001370053-18-000027.txt	Edgar Link	pending
0001370053-18-000027-xbrl.zip	Edgar Link	pending
anab-20180331.xml	Edgar Link	completed
anab-20180331.xsd	Edgar Link	pending
anab-20180331_cal.xml	Edgar Link	unprocessable
anab-20180331_def.xml	Edgar Link	unprocessable
anab-20180331_lab.xml	Edgar Link	unprocessable
anab-20180331_pre.xml	Edgar Link	unprocessable
anab-33118x10q.htm	Edgar Link	pending
anab-33118x10qxexx311.htm	Edgar Link	pending
anab-33118x10qxexx312.htm	Edgar Link	pending
anab-33118x10qxexx321.htm	Edgar Link	pending
anab-33118x10qxexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
milestonecharta03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
AnaptysBio Inc Stock $anab

2018 Q2 Form 10-Q Financial Statement

#000137005318000027 Filed on May 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB AnaptysBio Inc Stock $anab

2018 Q2 Form 10-Q Financial Statement

#000137005318000027 Filed on May 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
AnaptysBio Inc Stock $anab